ALTSTATION.IO

Cencora, Inc. (COR) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$357.15

Change

+1.42%

Market Cap

$69.48B

Avg Volume

1.4M

Company Overview

Cencora, Inc. is a key player in the healthcare sector, focusing on the distribution of pharmaceutical products. The company supplies a wide range of products, including generic and injectable pharmaceuticals, over-the-counter healthcare items, and various medical supplies. Their clientele includes acute care hospitals, health systems, retail pharmacies, and other healthcare providers, both in the U.S. and internationally. Additionally, Cencora offers services like pharmacy management, data analytics, and clinical trial support, emphasizing comprehensive solutions for the healthcare industry.

Cencora operates in a competitive landscape dominated by several large players, including McKesson Corporation and Cardinal Health. It positions itself as a challenger in the medical distribution market with a diversified service portfolio that spans acute and long-term care, as well as specialty pharmaceuticals. Their edge lies in their established relationships within the healthcare system and the ability to provide a robust suite of services beyond mere distribution. However, challenges include navigating regulatory pressures and intense competition from both established and emerging distributors.

Currently, Cencora is in a growth phase, especially following its rebranding from AmerisourceBergen in August 2023. This name change reflects a strategic pivot towards enhancing its global presence and expanding its range of services. Recent milestones, such as increased investments in technology and logistics capabilities, position the company well to capitalize on the growing demand for healthcare products and services. Overall, Cencora is not just maintaining its place in the market; it is actively seeking to expand its influence and market share.

Key Financials

Market Cap

$69.48B

Revenue

$325.78B

EBITDA

$5.04B

Gross Margin

3.6%

Profit Margin

0.5%

Revenue Growth

5.5%

Total Cash

$1.75B

Total Debt

$9.91B

Free Cash Flow

$3.51B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

42.77

Forward P/E

18.22

Beta

0.69

52-Week High

$377.54

52-Week Low

$237.71

EPS

$8.35

50-Day Avg

$347.71

200-Day Avg

$314.77

Price/Book

36.41

Technical Analysis

Cencora, Inc. (COR) has demonstrated a strong upward trend over the past 52 weeks, gaining 46.9% from approximately $243 in February of the previous year to its current price of $357.15. Key resistance levels can be identified around $359.25, while support levels are evident near the $250 mark. The stock has shown several bullish patterns, including higher highs and higher lows, indicative of sustained positive momentum. Recently, momentum has picked up significantly, peaking at around $375 in January before a slight pullback, which suggests potential profit-taking or market corrections. Currently trading near its 52-week high, the price implies strong market interest and positive sentiment, as it remains firmly in the upper range of its yearly performance. Continued monitoring of price levels around $359.25 will be essential for assessing potential breakout opportunities or reversal risks.

Recent News and Developments

Here’s a summary of the latest news and developments for Cencora, Inc

(COR) stock in the past week:

Market Update

### Cencora Reports Q1 Fiscal 2026 Earnings Beat, Raises Operating Income Guidance

Cencora, Inc

announced its first-quarter fiscal 2026 results on Wednesday, February 4, 2026, reporting adjusted earnings per share (EPS) of $4.08, which surpassed the Zacks Consensus Estimate of $4.07 and the analyst consensus of $4.04. This represents a 9.4% increase year-over-year. While revenue of $85.93 billion rose 5.5% year-over-year, it slightly missed the consensus estimate of $86.02 billion to $86.18 billion. Despite the mixed results, the company raised its fiscal 2026 adjusted operating income growth guidance to 11.5% to 13.5%, up from the previous range of 8% to 10%, partly reflecting the completed acquisition of OneOncology.

Market Sentiment and Analyst Recommendations

Bull Case

Cencora just raised full-year operating income guidance to 11.5-13.5% growth after the OneOncology acquisition closed, signaling management confidence in execution. The company beat EPS by a hair at $4.08 versus $4.04 consensus, with 9.4% year-over-year growth that shows pricing power and margin expansion working. Revenue of $325.78B on a 5.5% growth rate is solid for a healthcare distributor, and the specialty oncology play via OneOncology opens a higher-margin revenue stream that should expand net margins over time. The stock is trading at a 42.77 P/E on a company growing earnings double-digits, which is reasonable for a compounder with 46.9% gains already in the 52-week range. Analyst consensus sits at $399.80 target with 15 buy ratings, implying 12% upside from current levels. The cash position of $1.75B against $9.91B debt is manageable for a company generating serious operating cash flow.

Bear Case

The revenue miss of $86.02-86.18B consensus versus $85.93B actual is small but tells a story: top-line growth is slowing relative to guidance raises, which means the earnings beat came entirely from operational leverage and cost cuts, not organic demand. A 42.77 P/E multiple is expensive for a 5.5% revenue growth rate, even with double-digit operating income growth, and leaves little room for execution stumbles. International operating income declined sharply post-acquisition, a red flag that suggests integration challenges or geographic headwinds that management hasn’t fully explained. The stock already gained 46.9% in 52 weeks and just plunged 9% on earnings before rebounding, indicating volatility and potential profit-taking ahead. Healthcare distribution is a low-margin, competitive business facing pricing pressure from consolidators and PBMs; OneOncology’s $7.4B price tag is a big bet that specialty oncology margins hold up. The debt load of $9.91B is substantial and will require years of cash flow to delever if growth disappoints.

What to Watch

Monitor Q2 fiscal 2026 results in May for revenue growth acceleration and whether the OneOncology integration is actually driving margin expansion or dragging on profitability. Watch for guidance reaffirmation or another raise on operating income; if management maintains the 11.5-13.5% range through the year, the bull case strengthens. Track international segment performance specifically, since the sharp decline post-acquisition suggests either real operational issues or one-time charges that need clarification. The stock needs to hold above $359.25 resistance to confirm the uptrend; a break below $340 would signal a failed rebound and potential re-test of $320 support. Listen for commentary on specialty pharma pricing and reimbursement trends, since OneOncology’s value depends on oncology drug pricing remaining stable. Watch the debt-to-EBITDA ratio each quarter; if leverage stays above 2.5x while growth slows, refinancing risk becomes real.

Analyst Consensus

BUY

Based on 15 analyst opinions

Low Target

$340.00

Mean Target

$399.80

High Target

$440.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Distribution

Employees

47,000

Earnings & Dividends

Next Earnings

Feb 04, 2026

EPS (Trailing)

$8.35

Dividend Yield

68.0%

Payout Ratio

27.0%

Frequently Asked Questions

Is COR a good stock to buy?

Yes, analysts recommend a “BUY” rating for Cencora, Inc. (COR) with a target price of $399.80. Given the current stock price of $357.15, this suggests a potential upside of about 11.5%.

What is COR’s price target?

The analyst price target for Cencora, Inc. is $399.80. This aligns with the current valuation metrics and reflects expected growth in the medical distribution sector.

Does COR pay a dividend?

Yes, Cencora, Inc. offers a substantial dividend yield of 68.0%. This level of yield is attractive for income-focused investors.

What is COR’s P/E ratio?

Cencora has a trailing P/E ratio of 42.77 and a forward P/E of 18.22. While the trailing P/E suggests potential overvaluation, the forward P/E indicates expectations for earnings growth.

What is COR’s market cap?

Cencora, Inc. has a market cap of $69.48 billion. This positions the company as a significant player in the healthcare and medical distribution sectors.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.